The Peptide Gold Rush Is Reshaping B2B Sourcing
Peptides used to be a quiet corner of pharmaceutical chemistry. Not anymore. A single therapeutic class — GLP-1 receptor agonists for obesity and diabetes — has pulled an…
Read article
First1BioLab News
Peptide industry insights.
Research and reporting on peptide raw materials, technology, regulation and professional sourcing.
Antimicrobial Peptides in Research: What B2B Buyers Should Verify
Antimicrobial peptides remain an active research area. A sourcing review should separate laboratory findings, clinical development and approved uses.
Read articleFermentation and Hybrid Routes in Peptide Manufacturing
Peptide production can use chemical, biological or hybrid routes. Buyers should compare process fit and verified output rather than assume one route is universally better.
Read articleSynthetic Long Peptides in Neoantigen Vaccine Research
Personalized peptide vaccines are being studied in clinical programs. Early immune-response findings create manufacturing questions, not a general claim of treatment benefit.
Read articleMicroneedle Delivery of Peptides: Development Considerations
Microneedle systems are being investigated as a delivery route for peptides. Formulation, device performance and clinical evidence remain product-specific.
Read articleAPAC Peptide API Supply: Capacity Claims and Qualification
Peptide manufacturing announcements across Asia signal investment, while actual supply depends on molecule-specific quality, availability and market authorization.
Read articleThe Peptide CDMO Capacity Race: What Expansion Means for B2B Buyers
Large investments are expanding peptide manufacturing, but qualified capacity, analytical controls and delivery timing still decide a sourcing plan.
Read articleFrom QMSR to Synthetic Peptide Guidance: The 2026 Regulatory Reset
FDA device quality rules, EMA synthetic-peptide guidance and WHO decisions affect different products in different ways. Buyers should separate their scopes.
Read articlePeptide Tech Frontiers 2026: AI Design, Oral Delivery and Manufacturing
AI-assisted sequence design, oral formulations and flow synthesis create different opportunities. Buyers need evidence for the capability they intend to purchase.
Read articleThe Consumerization of GLP-1: Oral Products and a Changing Demand Mix
Oral GLP-1 products are changing market access and format expectations, but peptide and non-peptide supply chains must be evaluated separately.
Read articleFrom Kilograms to Tonnes: What Peptide Raw-Material Scale-Up Must Control
Large-scale SPPS is expanding. Buyers still need to compare identity, impurity control, yield, analytical methods and lot-linked records.
Read articleThe GLP-1 Effect: How Peptide Therapeutics Became a Multi-Billion-Dollar Market
How GLP-1 demand, regional growth and peptide manufacturing capacity are changing sourcing decisions.
Read articleFrom Batch to Flow: The Manufacturing Technologies Redefining Peptide Scale-Up
A procurement-focused review of hybrid synthesis, continuous flow, inline analytics and peptide scale-up.
Read articleReading the FDA’s Peptide Rulebook: Compounding, PCAC, and What It Means for Buyers
A buyer-oriented overview of GLP-1 shortage rules, bulk substances, PCAC and U.S. sourcing risk.
Read articleThree Regulators, One Direction: How EMA and China NMPA Are Converging with FDA on Peptides
What peptide buyers should understand about EMA quality expectations, China filing paths and global dossier planning.
Read articleBeyond the Clinic: What the Consumer Peptide Boom Means for Ingredient Suppliers
Consumer search, beauty and personal-care signals that matter to peptide ingredient suppliers.
Read article